Integrative Cancer Therapies, 2023 Background: When it comes to chemotherapy, maintaining the dose and schedule of treatment are of vital importance, as clinical evidence suggests that dose intensity is associated with optimal treatment outcomes for various tumors.
Karen Y. Wonders PhD, FACSM +2 more
doaj +3 more sources
Relative dose intensity of systemic chemotherapy in an outpatient cancer center
Acta Medica Academica, 2010 Objective. This study was undertaken to determine the average relative dose intensity (RDI) of chemotherapy administered to patients in a community-based outpatient cancer center. Methods.
Christine Uptigrove +3 more
doaj +1 more source
Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma. [PDF]
Oncol Lett, 2022 The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine ...
Rožman S +3 more
europepmc +5 more sources
Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer [PDF]
Contemporary Oncology, 2020 Ilfad Blazevic +3 more
doaj +2 more sources
Relative Dose Intensity of Daratumumab, Lenalidomide, and Dexamethasone in Multiple Myeloma. [PDF]
Cancers (Basel)Background: Daratumumab (DARA), lenalidomide (LEN), and dexamethasone (DEX, DRd) are one of standards of care for patients with multiple myeloma (MM); however, the clinical impact of relative dose intensity (RDI) remains unclear. In this retrospective study, the aim was to analyze the relationship between the RDI and clinical outcomes in patients with ...
Suzuki K +7 more
europepmc +3 more sources
Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment [PDF]
PeerJ, 2023 Objectives To determine the relationship between chemotherapy dose delay/reduction with progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients treated with FOLFIRI based first-line chemotherapy in real-world ...
Xia Zhang +7 more
doaj +2 more sources
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. [PDF]
Blood Adv, 2022 N ...
Fresa A +22 more
europepmc +7 more sources
Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma. [PDF]
In VivoThe impact of enfortumab vedotin (EV) dose reduction and/or interruption on its efficacy for advanced urothelial carcinoma (UC) is unclear.We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to June 2024.
Furubayashi N +5 more
europepmc +3 more sources
Current Oncology, 2021 There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were ...
Suganija Lakkunarajah +5 more
doaj +1 more source
Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer. [PDF]
Cancer Epidemiol Biomarkers Prev, 2023 Abstract Background: Despite evidence that low muscle increases the risk of chemotoxicity, most chemotherapies are dosed on body surface area without considering body composition. Among 178 patients with colon cancer, we assessed muscle and adipose tissue with multiple techniques and examined ...
Cheng E +12 more
europepmc +3 more sources